Form 4: Century Therapeutics Officer Sells Shares Under 10b5-1 Trading Plan

Gregory Russotti, Chief Technology and Manufacturing Officer of Century Therapeutics, sold 586 shares of common stock at $2.50 per share on July 26, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Gregory Russotti, Chief Technology and Manufacturing Officer of Century Therapeutics, sold 586 shares of common stock on July 26, 2024.
• The sale was executed at a price of $2.50 per share.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on January 9, 2024.
• Following the transaction, Russotti directly owns 274,933 shares and indirectly owns 92,773 shares through the Gregory Russotti 2021 Family Trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily indicate a positive or negative outlook on the company.

Industry Context

Sales by insiders are a common occurrence, and the use of 10b5-1 trading plans allows insiders to sell shares at predetermined times to avoid accusations of trading on inside information. Investors often monitor insider transactions for signals about a company's prospects, but sales under 10b5-1 plans are generally viewed as less informative than discretionary trades.

Stakeholder Impact

• The sale of shares by a company officer could have a minor impact on shareholder sentiment, but the existence of a 10b5-1 trading plan mitigates concerns about insider trading.

Key Dates